Head-to-head · WeighScore
PreventiveMD vs Ro
The verdict
Ro takes it — 80.2/100 to 76.4/100.
Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | PreventiveMD | Ro |
|---|---|---|
| WeighScore | 76.4/100 | 80.2/100 |
| Grade | C | B− |
| Scorecard rank | #53 | #38 |
| Semaglutide | $83/mo (as low as, term not published, all-in, compounded) | Not disclosed |
| Tirzepatide | $97/mo (as low as, term not published, all-in, compounded) | Not disclosed |
| Coverage | 36 states | Multi-state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #53 · C
Strengths
- Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
- Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
- US-licensed provider reviews requests within 24 hours — no video visit required
- You aren't charged until a provider approves; checkout places an authorization hold only
- LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies
Where it loses points
- Both figures are 'as low as' rates and the qualifying term is not published anywhere — the checkout is gated, so whether $97 is month-to-month or a multi-month prepay cannot be established before signing up
- Brand-name routes are priced separately and do carry a fee: $49/mo membership plus medication from $149/mo for Foundayo and Wegovy, from $299/mo for Zepbound
- No state count is published, and a state-variant waitlist implies some states are unserved
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #38 · B−
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.